Phase
Condition
N/ATreatment
INS-GSH
Matched Placebos
Clinical Study ID
Ages 30-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
Documented clinical diagnosis of idiopathic PD
Modified HY stage < 5
Able to administer study drug or have a caregiver throughout the duration of thestudy to help administer drug
Willing to continue diet, exercise and medications reported at baseline consistentlythroughout participation in the trial. Essential changes are permitted
If taking PD medications or any nutraceuticals, must be on a stable dose for atleast 30 days prior to Screening Visit. Essential changes will be permitted.
If subject is taking chronic antidepressant or an anxiolytic, must be on a stabledose for at least 90 days prior to Screening. Essential changes will be permitted.
Exclusion
Key Exclusion Criteria:
Clinical diagnosis of Type 1 or Type 2 Diabetes Mellitus
Glycated hemoglobin (HbA1c) level ≥ 6.5%
History of hypoglycemia and/or documented plasma glucose levels of ≤ 50 mg/dL withor without symptoms of hypoglycemia
Mini-Mental State Exam (MMSE) score of ≤ 24 at Screening
Positive COVID-19 test at Screening and/or within 30 days of Screening
Change in or escalation of dose of a chronic therapeutic agent that has thepotential to impair cognitive functioning
Chronic inflammation of nasal cavity that may prevent absorption of study treatments
Insufficiently controlled respiratory disease (i.e., asthma, COPD).
History of any significant neurologic or psychiatric disease other than PD
Current diagnosis of epilepsy and had a history of seizures as an adult within 1year of Screening, or unexplained recent loss of consciousness, or history ofsignificant head trauma with loss of consciousness
History of non-lacunar ischemic and/or hemorrhagic stroke
Unstable or uncontrolled cardiac disease that could expose the subject to additionalsafety risks
Use of the following medications: Insulin or any other anti-hyperglycemic agent(s)except if used during isolated gestational diabetes, Supplementation with GSH or anymedication shown to increase glutathione, and Beta Blockers
Study Design
Connect with a study center
Institute for Neuroimmune Medicine
Davie, Florida 33314
United StatesActive - Recruiting
Las Mercedes Medical Research
Hialeah, Florida 33012
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.